Antares Pharma is a pharmaceuticals business based in the US. Antares Pharma shares (ATRS) are listed on the NASDAQ and all prices are listed in US Dollars. Antares Pharma employs 201 staff and has a trailing 12-month revenue of around $183.5 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $5.59 |
|---|---|
| 52-week range | $0.00 - $0.00 |
| 50-day moving average | $4.93 |
| 200-day moving average | $3.92 |
| Wall St. target price | $5.95 |
| PE ratio | 24.0948 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.23 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $5.59 from 2022-05-24
| 1 week (2024-07-15) | N/A |
|---|---|
| 1 month (2024-06-22) | N/A |
| 3 months (2024-04-22) | N/A |
| 6 months (2024-01-22) | N/A |
| 1 year (2023-07-22) | N/A |
|---|---|
| 2 years (2022-07-22) | N/A |
| 3 years (2021-07-26) | 26.76% |
| 5 years (2019-07-26) | 74.69% |
Valuing Antares Pharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Antares Pharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Antares Pharma's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 24x. In other words, Antares Pharma shares trade at around 24x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Antares Pharma's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $23.1 million.
The EBITDA is a measure of a Antares Pharma's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $183.5 million |
|---|---|
| Operating margin TTM | 10.43% |
| Gross profit TTM | $115.7 million |
| Return on assets TTM | 5.04% |
| Return on equity TTM | 26.61% |
| Profit margin | 21.9% |
| Book value | $1.03 |
| Market Capitalization | $955.1 million |
TTM: trailing 12 months
We're not expecting Antares Pharma to pay a dividend over the next 12 months.
Antares Pharma's shares were split on a 1:5 basis on 28 January 1999. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Antares Pharma shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Antares Pharma shares which in turn could have impacted Antares Pharma's share price.
Over the last 12 months, Antares Pharma's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Antares Pharma's is 1.1491. This would suggest that Antares Pharma's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Antares Pharma, Inc. , a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
We’ve rounded up stats on some of the most popular semiconductor stocks, along with information on how they compare and how to invest.
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.